The business and affairs of Mylan Inc. are managed under the oversight of the company's Board of Directors. The company’s bylaws and corporate governance principles detail certain of the Directors’ duties, rights and responsibilities.
Currently, the Board has seven committees, each operating pursuant to a written charter.
The Chief Executive Officer (CEO) and other senior leaders oversee management of company business. Duties and standards of conduct for employees, officers and directors are set forth in the company's Code of Business Conduct and Ethics, as well as in the Code of Ethics for the CEO, Chief Financial Officer (CFO) and Corporate Controller (CC).
To learn more about our leaders, click here
Sanjeev Sethi is the Chief Operating Officer in Mylan. In his career spanning over 2 decades, Sanjeev has held key leadership positions across critical functions such as R&D, Regulatory Affairs, Technical Services and Manufacturing.
Sanjeev leads various functions within Mylan including R&D, regulatory sciences, clinical operations, technical operations, portfolio management, medical and Product Safety & Risk Management (PRSM) operations. He also heads the Global Launch Management Group and oversees new product launches, globally.
Sanjeev joined Mylan in 2007, through the Matrix acquisition, and has held a series of increasingly significant positions with the company since then. Most recently, he was the Head of Global Injectable operations where he led the operational execution for all injectable products in Mylan’s portfolio. Prior to this, he held positions of Head of Global Scientific Affairs and Head of Global Generics R&D.
Sanjeev is armed with a master’s degree in Pharmaceutical Sciences from the Punjab University and holds 40 international patents to his credit.
Sanjeev was associated with Ranbaxy, Sandoz and Matrix Laboratories across functions like R&D, Regulatory Affairs, Technical Services and Manufacturing Operations through is career in the Pharmaceutical Industry.
President, India and Emerging Markets
Rakesh Bamzai is President, India Commercial and Emerging Markets at Mylan Pharmaceuticals Private Limited and Managing Director and CEO of Mylan Laboratories Limited. Based in Bangalore, Rakesh has close to three decades of experience in the Indian and global biopharmaceutical industry.
In his current role, Rakesh is responsible for leading Commercial Operations for Mylan’s branded, branded generics, generics, biosimilars, antiretroviral (ARV) and active pharmaceutical ingredient (API) businesses in India and Emerging Markets. During his tenure with Mylan, Rakesh has championed various initiatives to transform Mylan’s businesses across the highly dynamic countries within the region. He has been instrumental in establishing a robust commercial and distribution platform and forged strategic partnerships with the aim of enhancing access and affordability in line with the company’s vision. Further, he has led multiple integration efforts to consolidate and streamline businesses within Mylan’s India and Emerging Markets region.
Rakesh also has developed an expertise in the global biopharmaceutical business throughout his career and has a track record of scaling up businesses from scratch. With a keen eye for leveraging valuable therapies and portfolios that fulfill unmet needs, he has led marketing efforts that have influenced development pipelines created successful pillar brands across therapies in various international markets.
Rakesh studied Chemical Technology at the University Department of Chemical Technology, now known as the Institute of Chemical Technology at the University of Mumbai, where he was named a ‘Distinguished Alumni’ by the Vice Chancellor of the university.